期刊
ANNALS OF NEUROLOGY
卷 88, 期 2, 页码 396-406出版社
WILEY
DOI: 10.1002/ana.25797
关键词
-
资金
- NIH National Institutes of Child Health and Disease [3U54-HD061222-14S1]
- Vanderbilt Intellectual and Developmental Disabilities Research Center [U54HD083211]
Objective Rett syndrome,CDKL5-deficiency disorder,FOXG1disorder, andMECP2duplication disorder are developmental encephalopathies with shared and distinct features. Although they are historically linked, no direct comparison has been performed. The first head-to-head comparison of clinical features in these conditions is presented. Methods Comprehensive clinical information was collected from 793 individuals enrolled in the Rett and Rett-Related Disorders Natural History Study. Clinical features including clinical severity, regression, and seizures were cross-sectionally compared between diagnoses to test the hypothesis that these are 4 distinct disorders. Results Distinct patterns of clinical severity, seizure onset age, and regression were present. Individuals withCDKL5-deficency disorder were the most severely affected and had the youngest age at seizure onset (2 months), whereas children withMECP2duplication syndrome had the oldest median age at seizure onset (64 months) and lowest severity scores. Rett syndrome andFOGX1were intermediate in both features. Smaller head circumference correlates with increased severity in all disorders and earlier age at seizure onset inMECP2duplication syndrome. Developmental regression occurred in all Rett syndrome participants (median = 18 months) but only 23 to 34% of the other disorders. Seizure incidence prior to the baseline visit was highest forCDKL5deficiency disorder (96.2%) and lowest for Rett syndrome (47.5%). Other clinical features including seizure types and frequency differed among groups. Interpretation Although these developmental encephalopathies share many clinical features, clear differences in severity, regression, and seizures warrant considering them as unique disorders. These results will aid in the development of disease-specific severity scales, precise therapeutics, and future clinical trials. ANN NEUROL 2020
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据